All AbMole products are for research use only, cannot be used for human consumption.
WZ8040 is a novel EGFR inhibitor which suppresses the growth of EGFR-T790M-containing cell lines and inhibits EGFR phosphorylation. WZ8040 has a basic chemical framework (covalent pyrimidine) which is different from that of other EGFR inhibitors. WZ8040 is 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wildtype EGFR, than quinazoline-based EGFR inhibitors (HKI-272 and CL-387,785) in vitro.
 |
Source | Nature (2009). Figure 2. WZ8040 |
| Method | Immunohistochemical analysis | |
| Cell Lines | 3T3 cells | |
| Concentrations | 10 ng/ml | |
| Incubation Time | 16 h | |
| Results | These compounds were 3- to 100-fold less potent, with WZ compounds being least potent, than CL-387,785 and HKI-272 at inhibiting the growth of the EGFR WT cells. |
 |
Source | Nature (2009). Figure 1. WZ8040 |
| Method | immunoblot | |
| Cell Lines | PC9 GR cells | |
| Concentrations | 10 ng/ml | |
| Incubation Time | 16 h | |
| Results | We observed a similar increased potency of the WZ compounds in the H1975 (L858R/T790M) cell line and in Ba/F3 cells harbouring EGFR T790M |
| Cell Experiment | |
|---|---|
| Cell lines | NSCLC or Ba/F3 cells |
| Preparation method | Cell proliferation and growth assays NSCLC or Ba/F3 cells were exposed to treatment for 72 hours and the number of cells used per experiment determined empirically and has been previously established2,7. All experimental points were set up in six to twelve wells and all experiments were repeated at least three times. The data was graphically displayed using GraphPad Prism version 5.0 for Windows, (GraphPad Software; www.graphpad.com). The curves were fitted using a non-linear regression model with a sigmoidal dose response. |
| Concentrations | 0~10 μM |
| Incubation time | 72 h |
| Animal Experiment | |
|---|---|
| Animal models | EGFR-TL (T790M/L858R) mice and EGFR exon19 Deletion-T790M (TD) inducible bitransgenic mice |
| Formulation | NMP (10% 1-methyl-2-pyrrolidinone: 90% PEG-300) |
| Dosages | 25mg/kg daily |
| Administration | gavage |
| Molecular Weight | 481.01 |
| Formula | C24H25ClN6OS |
| CAS Number | 1214265-57-2 |
| Solubility (25°C) | DMSO 76 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[1] Zhou W, et al. Nature. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.
| Related EGFR/HER2 Products |
|---|
| Sevabertinib
Sevabertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antitumor activity. |
| BPIQ-I
BPIQ-I (PD 159121) is a potent and ATP-competitive EGFR tyrosine kinase inhibitor.. |
| HKI-357
HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 with IC50s of 34 nM and 33 nM, respectively. |
| SJF-1528
SJF-1528 is a potent EGFR PROTAC degrader with DC50 values of 39.2 nM and 736.2 nM for wild-type EGFR in OVCAR8 cells and Exon 20 Ins mutated EGFR in HeLa cells. |
| CH7233163
CH7233163 is a noncovalent ATP-competitive inhibitor for EGFR-Del19/T790M/C797S. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
